Conversely, failure of pET to achieve optimal suppression of tumor cell proliferation (post-pET Ki67 < 10%) was 1.8-fold more common in ERBB2-mutated ILC compared to ILC harboring wild-type ERBB2 (10/14, 71% versus 65/165, 39%, P = 0.0248). Here, ERBB2 is linked to neoplasm.